Truist raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $89 and keeps a Hold rating on the shares. The firm is citing the company’s clean earnings beat and guidance raise while also noting that the performance was driven by continued double-digit TAVR growth momentum, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
- Edwards Lifesciences price target raised to $100 from $98 at BTIG
- Edwards Lifesciences price target lowered to $85 from $87 at Canaccord
- Edwards Lifesciences price target raised to $87 from $85 at Baird
- Edwards Lifesciences price target lowered to $100 from $103 at BofA